Loading…
Loading…
TTI does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage, for any covered stock.
TapClick below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
TapClick below to see what's inside, then upgrade to unlock for TTI and 80,000+ other tickers.
See price against where its own fundamentals say it should trade. The shaded gap is the discount or premium, across five valuation lenses.
TapClick below to see what's inside, then upgrade to unlock for TTI and 80,000+ other tickers.
See exactly how TTI's revenue becomes profit: a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for TTI and 80,000+ other tickers.
TETRA Technologies, Inc. (TTI) is a diversified enterprise that delivers a range of services to the oil and gas industry. The company organizes its operations into two primary divisions: Completion Fluids & Products, and Water & Flowback Services. The Completion Fluids & Products segment is responsible for the production and distribution of specialized chemical formulations, such as clear brine fluids, various additives, and complementary services. These products are vital for well drilling, completion, and workover procedures in the oil and gas sector, with a market presence spanning the…
Investigator-initiated study led by Dr. Larry Greenbaum of Emory University to evaluate once-daily oral powder TTI-0102, designed to improve adherence San Diego, California--(Newsfile Corp. - October 22, 2026) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQB: TTIPF) ("Thiogenesis" or the "Company") today announced that the U.S. Food and Drug Administration ("FDA") has cleared its Investigational New Drug ("IND") application for TTI-0102 in nephropathic cystinosis. On October 16, 2026, the FDA issued a "Study May Proceed" letter for IND 184780.
SPRING, Texas, Sept. 30, 2026 /PRNewswire/ -- TETRA Technologies, Inc. (NYSE: TTI) will release Third Quarter 2026 results after the market closes on November 2, 2026 and will host a conference call to discuss the results and outlook on November 3, 2026, at 10:00am ET.
Valaris (NYSE: VAL - Get Free Report) and Tetra Technologies (NYSE: TTI - Get Free Report) are both energy companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends and earnings. Profitability This table compares Valaris and Tetra Technologies' net
MIND Technology (NASDAQ: MIND - Get Free Report) and Tetra Technologies (NYSE: TTI - Get Free Report) are both small-cap energy companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, dividends, earnings and analyst recommendations. Insider and Institutional Ownership 9.8% of MIND
San Diego, California--(Newsfile Corp. - September 21, 2026) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQB: TTIPF) ("Thiogenesis" or the "Company"), a clinical-stage biopharmaceutical company developing sulfur-based therapeutics for serious pediatric diseases, today announced the results of its Annual and Special Meeting of Shareholders ("Meeting") held on September 8, 2026, and provided a corporate update highlighting recent clinical, regulatory, and financial milestones. Meeting Results All items of business put before shareholders at the Meeting were approved by the requisite majority of votes cast.